| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
23070 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Pembrolizumab (Keytruda®) is indicated in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced, unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1 |
| Rapid review commissioned |
21/11/2023 |
| Rapid review completed |
18/12/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
09/01/2024 |
| Pre-submission consultation with Applicant |
30/01/2024 |
| Full submission received from Applicant |
01/08/2024 |
| Preliminary review sent to Applicant |
09/05/2025 |
| NCPE assessment re-commenced |
06/06/2025 |
| Follow-up to preliminary review sent to Applicant |
01/07/2025 |
| NCPE assessment re-commenced |
10/07/2025 |
| Additional follow-up to Preliminary Review sent to Applicant |
24/07/2025 |
| NCPE assessment re-commenced |
25/07/2025 |
| Factual accuracy sent to Applicant |
01/08/2025 |
